Predictive factors of treatment interruption duration in a cohort of HIV-1 infected patients with CD4 count greater than 350 cells per mm3

Medecine et Maladies Infectieuses

Volumn 36, Issue 6, 2006, Pages 335-339

  Fillaux, J ^a,b   Delpierre, C ^a,b   Alvarez, M ^a   Jaafar, A ^a   Marchou, B ^a   Massip, P ^a   Cuzin, L ^a  

^a CHU PURPAN   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

CD4 cell count; HIV; Treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; COMPUTER; FEMALE; HAZARD ASSESSMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; PREDICTION; SURVIVAL; TIME SERIES ANALYSIS; VIRUS LOAD; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION; IMMUNOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; TIME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TIME FACTORS; VIRAL LOAD;

EID: 33746257207     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2006.01.009     Document Type: Article

References (23)

1. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338 13 (1998) 853-860
2. Sommet A., Delpierre C., Cuzin L., Jaafar A., Marchou B., and Massip P. Anti-retroviral treatment interruptions in HIV-infected adults: causes, clinical, immunological and virological consequences. Rev. Med. Interne 24 6 (2003) 350-357
3. Hirschel B. Planned interruptions of anti-HIV treatment. Lancet Infect. Dis. 1 1 (2001) 53-59
4. Rosenberg E.S., Altfeld M., Poon S.H., Phillips M.N., Wilkes B.M., Eldridge R.L., et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407 6803 (2000) 523-526
5. Fagard C., Oxenius A., Gunthard H., Garcia F., Le Braz M., Mestre G., et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch. Intern. Med. 163 10 (2003) 1220-1226
6. Deeks S.G., and Hirschel B. Supervised interruptions of antiretroviral therapy. AIDS 16 Suppl 4 (2002) S157-S169
7. Garcia F., Plana M., Ortiz G.M., Bonhoeffer S., Soriano A., Vidal C., et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 15 9 (2001) F29-F40
8. Ruiz L., Martinez-Picado J., Romeu J., Paredes R., Zayat M.K., Marfil S., et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 14 4 (2000) 397-403
9. Rey D., Schmitt M.P., Hess-Kempf G., Krantz V., Partisani M., Bernard-Henry C., et al. Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results. Pathol. Biol. (Paris) 49 7 (2001) 559-566
10. Izopet J., Souyris C., Sandres-Saune K., Puissant B., Obadia M., Pasquier C., et al. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype. J. Med. Virol. 68 3 (2002) 305-310
11. Izopet J., Massip P., Souyris C., Sandres K., Puissant B., Obadia M., et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 14 15 (2000) 2247-2255
12. Deeks S.G., Grant R.M., Wrin T., Paxinos E.E., Liegler T., Hoh R., et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 17 3 (2003) 361-370
13. Ananworanich J., Nuesch R., Le Braz M., Chetchotisakd P., Vibhagool A., Wicharuk S., et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 17 15 (2003) F33-F37
14. Ananworanich J, Cardiello P, Srasuebkul P, Samor T, Hassink E, Mahanontharit A, et al. HIV-NAT 001.4: prospective randomized trial of structured treatment interruption in patients with chronic HIV infection. In: Tenth conference on retroviruses and opportunistic infections; 2003; Boston, USA; 2003.
15. Dybul M., Nies-Kraske E., Daucher M., Hertogs K., Hallahan C.W., Csako G., et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J. Infect. Dis. 188 3 (2003) 388-396
16. Dybul M., Nies-Kraske E., Dewar R., Maldarelli F., Hallahan C.W., Daucher M., et al. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J. Infect. Dis. 189 11 (2004) 1974-1982
17. Krolewiecki AJ, Zala C, Gun A, Ochoa C, Perez H, Bouzas MB, et al. Treatment discontinuation in patients who started antiretroviral therapy following the 1996 IAS-USA recommendations. A prospective randomized trial. In: XIV international AIDS conference; 2002 July; Barcelona, Spain; 2002.
18. Maggiolo F., Ripamonti D., Gregis G., Quinzan G., Callegaro A., and Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 18 3 (2004) 439-446
19. Tarwater P.M., Parish M., and Gallant J.E. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin. Infect. Dis. 37 11 (2003) 1541-1548
20. Ruiz L, Gomez L, Domnigo P, Romeu J, Tambussi G, Martinez-Picado J, et al. A multi-center, randomized controlled clinical trial of continuous vs. intermittent HAART guided by CD4+ T-cell counts and plasma HIV-1 RNA levels. In: Tenth conference on retroviruses and opportunistic infections; 2003; Boston, USA; 2003.
21. rd annual interscience conference on antimicrobial agents and chemotherapy; 2003 September 14-17; Chicago: Washington, DC: American Society for Microbiology; 2003.
22. Pugliese P., Cuzin L., Enel P., Agher R., Alfandari S., Billaud E., et al. NADIS 2000, development of an electronic medical record for patients infected by HIV, HBV and HCV. Presse Med. 32 7 (2003) 299-303
23. Gianotti N., Soria A., Galli L., Castagna A., Cernuschi M., Hasson H., et al. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy. J. Med. Virol. 72 2 (2004) 181-186